Tofacitinib is an oral drug used for treating rheumatoid arthritis. JAKs are enzymes (proteins) that regulate chemical signaling pathways that control biologic processes such as blood formation and the immune response that causes the pain, tenderness and swelling of inflammation.
Tofacitinib is an Janus kinase inhibitor. It works by blocking the action of the enzyme, Janus kinase. This decreases inflammation and joint damage in rheumatoid arthritis.
Major & minor side effects for Tofacitinib
- Bladder pain
- Blurred vision
- Chills
- Fast or slow heartbeat
- Runny Nose
- Bloating
- Unsual tiredness or weakness
- Nausea and vomiting
- Diarrhea
This medicine is not recommended for use in pregnant and breastfeeding women unless necessary.
Use of this medicine may cause dizziness or blurring of vision in some patients.
Use of this medicine may cause malignancy or reactivation of a previously treated malignancy.
This medicine should be used with extreme caution in patients with or who are at risk of gastrointestinal perforation since it may worsen the patient's condition.
Use of this medicine may affect the immune system making you susceptible to opportunistic infections from a wide variety of pathogens.
This medicine is not recommended for use in patients below 18 years of age since the safety and efficacy of use are not clinically established.
Use of this medicine may increase the levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides.
This medicine may increase the risk of non-melanoma skin cancer including basal cell, squamous cell, and Merkel cell carcinoma.
This medicine should be used with caution in patients with liver and kidney impairment due to the increased risk of adverse effects.